trending Market Intelligence /marketintelligence/en/news-insights/trending/_lp7juji28m7LrNR84WjpA2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Hemogenyx Pharmaceuticals director to resign

Video

Climate Credit Analytics: Linking climate scenarios to financial impacts

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Blog

COVID-19 Impact & Recovery: Private Equity


Hemogenyx Pharmaceuticals director to resign

Hemogenyx Pharmaceuticals Plc said Robin Campbell would resign as a nonexecutive director, effective Jan. 5, 2019.

London-based Hemogenyx Pharmaceuticals is a preclinical-stage biotechnology company that focuses on the discovery, development and commercialization of novel therapies and treatments for blood diseases.